Investor Relations

BVAXF

Quote

Short

News

Articles

Message Board

BioVaxys Technology Corp (OTCMKTS : BVAXF ) News

News Releases

BVAXF News Releases

May 01, 2026 08:00:00 am

TheNewsWire

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

April 27, 2026 08:00:00 am

TheNewsWire

BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

March 17, 2026 04:30:00 pm

TheNewsWire

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

March 10, 2026 08:00:00 am

TheNewsWire

BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines

January 29, 2026 08:00:00 am

TheNewsWire

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

January 20, 2026 08:00:00 am

TMX Newsfile

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

January 15, 2026 08:00:00 am

TheNewsWire

BioVaxys 1Q2026 R&D and Collaborative Activity

January 08, 2026 08:00:00 am

Newsfile

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

December 31, 2025 08:00:00 am

TheNewsWire

2025 Corporate Review

December 17, 2025 10:03:00 am

AllPennyStocks.com

Phase 1 Results Drive New Attention to Breast Cancer Play

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News

Link Market Wire News to Your X Account